Terlipressin Dosing for Esophageal Variceal Bleeding

Standard Dosing Regimen

• The American Gastroenterological Association recommends an initial dose of 2 mg IV every 4 hours for the first 48 hours until bleeding is controlled, followed by a maintenance dose of 1 mg IV every 4 hours for a total treatment duration of 2-5 days 1, 2
• The initial phase (first 48 hours) dosing is 2 mg IV every 4 hours until bleeding is controlled, as recommended by the American Gastroenterological Association 1
• The maintenance phase dosing is 1 mg IV every 4 hours, as recommended by the American Association for the Study of Liver Diseases 1, 2
• The total treatment duration is 2-5 days, as recommended by the American Gastroenterological Association 1

Efficacy and Comparative Effectiveness

• Terlipressin is the only vasoactive drug proven to reduce bleeding-related mortality, according to the American College of Gastroenterology 3
• Efficacy is comparable to other vasoactive agents like octreotide and somatostatin in terms of hemostasis and survival, as stated by the American Association for the Study of Liver Diseases 3

Adverse Effects and Precautions

• Common adverse effects include abdominal pain, nausea, respiratory failure, diarrhea, and dyspnea, as reported by the American Gastroenterological Association 1, 4
• Terlipressin is contraindicated in patients with hypoxia or worsening respiratory symptoms, ongoing coronary, peripheral, or mesenteric ischemia, and oxygen saturation <90%, as stated by the American Gastroenterological Association 4, 5

Clinical Pearls

• The American College of Gastroenterology recommends that terlipressin should be initiated as soon as variceal bleeding is suspected, even before diagnostic endoscopy 3
• Endoscopic therapy (preferably endoscopic variceal ligation) should be performed as soon as possible, ideally within 12 hours of presentation, as recommended by the American Society for Gastrointestinal Endoscopy 3
• Prophylactic antibiotics should be administered concurrently, as stated by the Infectious Diseases Society of America 3
• For high-risk patients (Child-Pugh class C or Child-Pugh class B with active bleeding despite vasoactive therapy), early TIPS placement should be considered, as recommended by the American Association for the Study of Liver Diseases 3

Dosing Adjustment Considerations

• In patients with poor response, the maintenance dose can be increased to 2 mg IV every 4 hours, as recommended by the American Gastroenterological Association 1, 2
• In patients with hepatorenal syndrome, dose adjustment may be needed based on serum creatinine levels, as stated by the American Society of Nephrology 5, 6

Terlipressin for Gastrointestinal Bleeding

Specific Indication: Variceal Hemorrhage Only

• Terlipressin is indicated exclusively for bleeding esophageal or gastric varices secondary to portal hypertension in cirrhotic patients, and works by causing splanchnic vasoconstriction, reducing portal venous inflow and portal pressure, according to the American Association for the Study of Liver Diseases 7, 8

When and How to Use Terlipressin

• The American College of Gastroenterology recommends starting terlipressin immediately when variceal bleeding is suspected clinically, even before endoscopic confirmation, at a dose of 2 mg IV every 4 hours until bleeding is controlled 7, 8
• Variceal bleeding should be suspected in any cirrhotic patient presenting with upper GI bleeding, and terlipressin should be started immediately, as stated by the European Association for the Study of the Liver 7

Combination Therapy is Essential

• The American College of Radiology suggests that terlipressin should never be used as monotherapy, and the standard approach requires vasoactive drug therapy (terlipressin) started immediately, endoscopic band ligation performed within 12 hours, and prophylactic antibiotics to reduce mortality, bacterial infections, and rebleeding 7, 8, 9
• Combination therapy achieves 77% five-day hemostasis versus 58% with endoscopy alone, according to the American College of Radiology 9

Efficacy and Mortality Benefit

• Terlipressin achieves 85-90% initial bleeding control rates when combined with endoscopy, and significant reduction in early rebleeding when combined with endoscopic therapy, as stated by the American College of Radiology 9

Clinical Algorithm for Variceal Bleeding

• The American Association for the Study of Liver Diseases recommends suspecting variceal bleeding in any cirrhotic patient with upper GI bleeding, immediately starting terlipressin and antibiotic prophylaxis, performing endoscopy within 12 hours, and continuing terlipressin for 2-5 days 7, 8

Management of Variceal Hemorrhage with Terlipressin

Treatment Duration and Dosage

• The American Association for the Study of Liver Diseases recommends administering terlipressin for 2-5 days in the treatment of variceal hemorrhage, with recent evidence suggesting that 2 days may be sufficient in selected patients after successful endoscopic hemostasis 10, 11
• The initial dose of terlipressin should be 2 mg IV every 4 hours until bleeding is controlled, followed by a maintenance dose of 1 mg IV every 4 hours 10, 11, 12, 13
• The total duration of treatment should be 2-5 days according to current guidelines 10, 11, 12, 13, 14

Factors Influencing Treatment Duration

• Patients with Child-Pugh class A or B cirrhosis and no active bleeding during endoscopy may be considered for a shorter treatment duration of 2 days 10, 11
• Patients with Child-Pugh class C cirrhosis or active bleeding during endoscopy may require a longer treatment duration of up to 5 days 10, 11
• A high MELD score (>19) may also be a factor in favor of a longer treatment duration 15

Combination Therapy

• The American Association for the Study of Liver Diseases recommends that terlipressin should never be used as monotherapy, but rather in combination with endoscopic variceal ligation and antibiotic prophylaxis 10, 12, 13, 14
• Combination therapy has been shown to achieve 77% hemostasis at 5 days, compared to 58% with endoscopy alone 16, 15

Adverse Effects

• Terlipressin can cause significant adverse effects, including hyponatremia, myocardial ischemia, abdominal pain, and diarrhea 10, 11, 14
• The incidence of adverse effects is higher with longer treatment durations (24.32% with 5 days vs 10.8% with 2 days) 10, 11

Terlipresina Dosage in Variceal Hemorrhage

Standard Dosage Regimen

• The American Association for the Study of Liver Diseases recommends a terlipresina dosage of 2 mg IV every 4 hours for the first 48 hours to control bleeding, followed by 1 mg IV every 4 hours for a total duration of 2-5 days 17
• Terlipresina should be initiated immediately when variceal bleeding is suspected, even before endoscopic confirmation, with a dosage of 2 mg IV every 4 hours 17
• The maintenance dosage of 1 mg IV every 4 hours should be started after the initial 48 hours 17

Combination Therapy

• The European Association for the Study of the Liver recommends that terlipresina should never be used as monotherapy, and the standard management requires three simultaneous components: vasoactive therapy (terlipresina) started immediately, endoscopic band ligation within the first 12 hours, and prophylactic antibiotics (ceftriaxone 1 g IV every 24 hours for up to 7 days) 17

Special Considerations

• The American College of Gastroenterology suggests that patients with high risk of treatment failure, such as those with Child-Pugh class C or active bleeding during endoscopy, may require a longer duration of terlipresina treatment, up to 5 days 17
• The use of erithromycin (250 mg IV, 30-120 minutes before) should be considered before emergency endoscopy to improve visibility, in the absence of QT prolongation 17
• A restrictive transfusion strategy with a hemoglobin threshold of 7 g/dl and a target of 7-9 g/dl is recommended 17

Management of Variceal Hemorrhage with Terlipressin

Dosage Regimen

• The American Association for the Study of Liver Diseases recommends administering 2 mg IV of terlipressin every 4 hours for the first 48 hours to control bleeding, followed by a maintenance dose of 1 mg IV every 4 hours, with a total treatment duration of 2-5 days 18, 19
• A study demonstrated that a single dose of 2 mg IV of terlipressin acutely reduces the hepatic venous pressure gradient from 22.2 to 19.1 mmHg 20

Treatment Duration

• The treatment duration can be shortened to 2 days in selected patients with Child-Pugh class A or B cirrhosis without active bleeding identified during endoscopy 20
• The European Association for the Study of the Liver recommends a longer treatment duration of up to 5 days in patients with Child-Pugh class C cirrhosis, active bleeding during endoscopy, or a high MELD score 18

Combination Therapy

• The American College of Gastroenterology recommends that terlipressin should never be used as monotherapy, and that standard management requires three simultaneous components: terlipressin, endoscopic variceal ligation, and prophylactic antibiotics, such as ceftriaxone 1 g IV every 24 hours for up to 7 days 18

Safety Profile

• Common adverse events associated with terlipressin include abdominal pain, nausea, respiratory failure, diarrhea, and dyspnea 20
• Terlipressin increases adverse events 2.39 times compared to octreotide 20

Contraindications

• Absolute contraindications for terlipressin include hypoxia or worsening respiratory symptoms, coronary, peripheral, or mesenteric ischemia, and oxygen saturation <90% 18, 20

Management of Bleeding Esophageal Varices

Recommended Treatment

• The American Association for the Study of Liver Diseases recommends terlipressin as the first-line splanchnic vasoconstrictor for bleeding esophageal varices, with a relative risk of 0.66 for bleeding-related mortality, making it superior to other splanchnic vasoconstrictors 21
• Terlipressin is preferred due to its longer half-life and significantly fewer adverse effects compared to vasopressin, particularly avoiding severe cardiovascular complications like mesenteric and myocardial ischemia 22, 23

Alternative Agents

• Octreotide or somatostatin are acceptable alternatives to terlipressin, with comparable efficacy for hemostasis and survival, though they lack the mortality benefit 21
• The dosing protocol for octreotide is 50 μg IV bolus, then 50 μg/hr continuous infusion, and for somatostatin is 250 μg IV bolus, then 250 μg/hr continuous infusion 21

Combination Therapy

• The European Association for the Study of the Liver recommends combination therapy with terlipressin, endoscopic band ligation, and prophylactic antibiotics, achieving 77% five-day hemostasis versus only 58% with endoscopy alone 21

Special Considerations

• In patients presenting with hypotension, temporarily suspend any existing beta-blocker therapy, as these agents are contraindicated in hypotensive states despite their role in variceal bleeding prophylaxis 22, 23

Terlipressin Use in Gastrointestinal Bleeding – Evidence‑Based Recommendations

Indications for Terlipressin

• Terlipressin is indicated for bleeding esophageal varices in patients with cirrhosis – the drug should be started promptly when variceal bleeding is suspected in this population. 24
• Terlipressin may be considered for bleeding anorectal varices related to portal hypertension, although the supporting evidence is weak and extrapolated from esophageal variceal data. (Weak recommendation) 25, 26

Management of Non‑Variceal Upper GI Bleeding

• Endoscopic hemostasis is the primary therapeutic modality for non‑variceal sources (e.g., peptic ulcers, Mallory‑Weiss tears, angiodysplasia). 24
• Proton‑pump inhibitor therapy is recommended for peptic‑ulcer disease as part of the standard non‑variceal bleeding regimen. 24

Avoidance of Inappropriate Terlipressin Use

• Empirical administration of terlipressin to any cirrhotic patient with GI bleeding is not advised; its use should be limited to cases with clinical suspicion of variceal bleeding rather than merely the presence of cirrhosis. (Strong recommendation) 24